Home » Topics » BioWorld Science, Neurology/psychiatric

BioWorld Science, Neurology/psychiatric
RSS

Second ANAVEX2-73 trial confirms SIGMAR1 mRNA expression as predictive biomarker of response

June 29, 2021

Neurotrophic signaling deficiency exacerbates Alzheimer's risk factors

June 28, 2021

SAN-711 shows promising activity in rat model of orofacial pain

June 28, 2021

Asarina reports phase IIa topline data on sepranolone in menstrual migraine

June 28, 2021

Bristol Myers Squibb exercises option to U.S. license for Prothena's PRX-005

June 25, 2021

Fulcrum reports phase IIb data on losmapimod in FSHD

June 25, 2021

Mercaptor advances programs in COVID-19 brain inflammation and epilepsy

June 25, 2021

Karuna reports phase Ib data on KarXT in healthy elderly volunteers

June 25, 2021

uniQure agrees to acquire Corlieve Therapeutics and lead gene therapy program

June 23, 2021

Sosei opens phase I trial of CGRP receptor antagonist HTL-0022562

June 23, 2021

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for May 20, 2026.
News in brief
BioWorld Asia
BioWorld Asia briefs for May 19, 2026
WHO declares Ebola outbreak a public health emergency of international concern
BioWorld
The threat posed by the Ebola outbreak in the Democratic Republic of Congo has intensified, with the confirmation that it is caused by the Bundibugyo species of...
Nxera Pharma prepares and tests new GPR17 antagonists
BioWorld Science
Nxera Pharma UK Ltd. has identified new uracil nucleotide/cysteinyl leukotriene receptor (GPR17; P2Y-Like) antagonists potentially useful for the treatment of...
Regeneron’s fianlimab lags in melanoma, does $2.3B deal with Parabilis
BioWorld
Regeneron Pharmaceuticals Inc. stuck with the tradition of releasing bad news on Friday afternoon and good news on Monday morning with a pair of announcements...